版權說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權,請進行舉報或認領
文檔簡介
Advancementofdiagnosisandtherapyincardiomyopathies
心肌病診治進展
LIAOYu-HuaInstituteofCardiology,UnionHospital,TongjiMedicalCollegeofHuazhongUniversityofScienceandTechnology,Wuhan,China精選課件ContemporaryDefinitionsandClassificationoftheCardiomyopathies
(2006AHA)
Cardiomyopathiesareaheterogeneousgroupofdiseasesofthemyocardiumassociatedwithmechanicaland/orelectricaldysfunctionthatusually(butnotinvariably)exhibitinappropriateventricularhypertrophyordilatationandareduetoavarietyofcausesthatfrequentlyare
genetic.Cardiomyopathieseitherareconfinedtotheheartorarepartofgeneralizedsystemicdisorders,oftenleadingtocardiovasculardeathorprogressiveheartfailure–relateddisability.MaronBJ,etal.Circulation,2006,113:1807-1816精選課件ClassificationCardiomyopathiescanbemosteffectivelyclassifiedasprimary:
genetic,mixed(geneticandnongenetic),acquired;and
secondaryPrimarycardiomyopathiesarethosesolelyorpredominantlyconfinedtoheartmuscleandarerelativelyfewinnumberSecondary
cardiomyopathiesshowpathologicalmyocardialinvolvementaspartofalargenumberandvarietyofgeneralizedsystemic(multiorgan)disordersMaronBJ,etal.Circulation,2006,113:1807-1816精選課件MaronBJ,etal.Circulation,2006,113:1807-1816精選課件DilatedCardiomyopathyDilatedformsofcardiomyopathyarecharacterizedbyventricularchamberenlargementandsystolicdysfunctionwithnormalLVwallthickness;usuallydiagnosisismadewith2-dimensionalechocardiographyDCMisacommonandlargelyirreversibleformofheartmusclediseasewithanestimated
prevalenceof1:2500;itisthethirdmostcommoncauseofheartfailureandthemostfrequentcauseofhearttransplantationMaronBJ,etal.Circulation,2006,113:1807-1816精選課件DCMphenotypewithgeneticoccurrencAbout20%to35%ofDCMcaseshavebeenreportedasfamilial,althoughwithincompleteandage-dependentpenetrance,andlinkedtoadiversegroupof20lociandgenes.DCMisalsocausedbyanumberofmutationsinothergenesencodingcytoskeletal/sarcolemmal,nuclearenvelope,sarcomere,andtranscriptionalcoactivatorproteins.ThemostcommonoftheseprobablyisthelaminA/Cgene,alsoassociatedwithconductionsystemdisease,whichencodesanuclearenvelopeintermediatefilamentprotein.MaronBJ,etal.Circulation,2006,113:1807-1816精選課件DCMphenotypewithsporadicoccurrenceInfectiousagents,particularlyviruses(coxsackievirus,adenovirus,parvovirus,HIV);bacterial;fungalrickettsial;myobacterial;andparasiticOthercausesincludetoxins;chronicexcessiveconsumptionofalcohol;chemotherapeuticagents;metalsandothercompounds;autoimmuneandsystemicdisorders;pheochromocytoma;neuromusculardisorderssuchasDuchenne/BeckerandEmery-Dreifussmusculardystrophies;andmitochondrial,metabolic,endocrine,andnutritionaldisordersMaronBJ,etal.Circulation,2006,113:1807-1816精選課件Criteria
①leftventricularend-diastolicdimension(LVEDd)>2.7cm/m2②leftventricularejectionfraction(LVEF)<45%and/orfactionalshortening
<25%
Exclusion:①hypertension,②CHD,③long-termoverdosedrinkingalcohol,④persistencesupraventriculararrhythmia,⑤systemicdisease,⑥pericardialdisease,⑦congenitalheartdisease,⑧pneumocardialdisease
DiagnosticcriteriaofidiopathicdilatedcardiomyopathyManolioTA,etal.AmJCardiol,1992,69:1459–66精選課件①diagnosticcriteriaofdilatedcardiomyopathy②Thediagnosisoffamilialdilatedcardiomyopathyis
made:1.inthepresenceoftwoormoreaffectedindividualsinasinglefamily2.orinthepresenceofafirst-degreerelativeofadilatedcardiomyopathypatient,withwelldocumentedunexplainedsuddendeathat<35yearsofageDiagnosis
offamilialdilatedcardiomyopathyMestroniL,etal.
EuroHeartJ,1999,20:93–102精選課件①diagnosticcriteriaofdilatedcardiomyopathy
②immunologicmarkers—anti-heartantibodiesaremainmarkers1including:anti-ANTAb、anti-?1-receptorAb、anti-MHCAb、anti-M2-receptorAb
Secondarymarkersincluding:
persistentviralinfectionTh2cellpredominancecytokinesgenetypeofhumamleucocyteantigenDiagnosis
ofimmune
dilatedcardiomyopathy
1苑海濤,廖玉華等.臨床心血管病雜志,2000,16:313-315精選課件AnalysisofautoantibodyindilatedcardiomyopathyANT31*(64.6%)4(8.3%)64.6%91.7%β126*(54.2%)4(8.3%)54.2%91.7%M220*(41.7%)3(6.3%)41.7%93.7%MHC23*(47.9%)2(4.2%)47.9%95.8%
positiveofautoantibodyinDCM
AHAinDCMPeptides
DCMgroup
(n=48)
HDgroup
(n=48)
sensitivity
specificity
n(%)n(%) ComparedwithHDgroup*p<0.005苑海濤,廖玉華.臨床心血管病雜志,2000,16:313精選課件ImmunopathogenesisinDCMVoltage-gatingCa-channelsCa-overloadCelldamageCardiacdilationReceptor-gatingCa-channelsVirusinfectionandautoimmunityresponseDCMAnti-ANT-AbAnti-?1-RAb精選課件TreatmentofDCM1、Conventionaltreatmentofheartfailure2、Preventembolism3、PreventSCD4、Improvecardiacmetabolism5、Cardiacresynchronizationtherapy6、Cardiactransplantation7、ImmunologictherapyinDCM精選課件1.β-receptorblockerToinhibittheanti-β1-Abmediatedmyocardiualdamage,especiallyinearlystageEspeciallysuitforthepatientswithtachycardiaorventriculararrhythmias,orwithanti-β1-AbpatientsDose:metroprolol6.25mgBidto12.5~100mgBid,slowlytitrateBlockedautoantibodiesresponse(1)精選課件
MDCtrial
Patients345,MGn=177andPGn=16816-75yearsofage
Metoprolol10mg/day→100~150mg/day
therapyofHF:digitalis、diuretics、ACEI
Followingup18months
MetoprololisindicatedtoimprovequanlityoflifeinheartfailurewithDCMβ-receptorblocker
clinicaltrialinDCMWaagsteinF,etal.Lancet,1993,342:1441-46
精選課件2.DiltiazemFrequeceofAnti-ANTantibodyispositiveabout60%-95%Mechanism:Anti-ANTantibodyincreasedCacurrentofmyocardialcell.DiltiazemcouldinhibittheantibodymediatedmyocardialdamageandprotectmyocardiumDiltiazemmightbeusedinearlystageofDCMDosage:diltiazem30mgtid
Blockedautoantibodiesresponse
(2)精選課件CalciumantagonistclinicaltrialinDCMDiDitrialPatients186,DGn=92andPGn=9418~70yearsofagetheadjuncttherapyofdiltiazem60~90mgtidonstandardtreatmentDiDitrialisshowedtoimprovecardiacfunction,exercisecapacityandsubjectivestatusinDCMFigullaHR.Circulation,1996,94:346-352.精選課件CalciumantagonistclinicaltrialinDCMISDDCtrialToevaluateeffectsofdiltiazemonheartfunctionandprognosisinDCMMultiplecentre,random,placebo-control
Followingup6~12monthsPatients221,PGn=107andDGn=114,46±12yearsofageDiltiazem60~90mg/dayorVitB160mg/day
TherapyofHF:digoxine,diuretics,ACEILiaoYH.IntJCardiol,1998,64:25-30.精選課件ISDDCtrial
PrognosisanalysisinDCM
PlaceboDiltiazemn=107n=114Outpatienttreatment63(58.9)102(89.5)***
Repeatedhospitalization44(41.1)12(10.5)***Death12(11.2)4(3.5)**Comparedwithplacebogroup**p<0.05,***p<0.01LiaoYH.IntJCardiol,1998,64:25-30.精選課件
BeforeAfterLVEDd>70mm(n=28)
LVEDd77.61±5.3874.50±8.92*
EF27.68±11.6933.71±12.64*
LVEDd<70mm(n=86)
LVEDd61.34±4.9156.88±5.32**
EF38.76±8.7546.07±7.88**
Comparedwithbeforetreatment,*p>0.05,**p<0.01
ISDDCtrialSubgroupanalysisofheartfunctionLiaoYH.IntJCardiol,1998,64:25-30.精選課件HeartimageafterdiltiazemtreatedDCM2000-8-11CTR0.451999-1-18CTR0.51998-9-17CTR0.6精選課件ISDDCtrialconclusionLiaoYH.IntJCardiol,1998,64:25-30.diltiazemissafeandeffectiveinthetreatmentofDCMtheactionmechanismmightbeinterventioninantibody-mediatedmyocardialdamageandprotectionofmyocardiumdiltiazemismoresuitablefortreatmentof
theearlystageinDCM
精選課件PathogenesisandtreatmentinDCM?1-blocksDiltiazemVoltage-gatingCa-channelsCa-overloadCelldamageCardiacdilation
Receptor-gatingCa-channelsVirusinfectionandautoimmunityresponseAnti-ANT-AbAnti-?1-RAbTherapyofHFDCMHFnoHFSevereHFLiaoYH.2001精選課件ImmunoadsorptionofautoantibodiesAnti-β1-adrenoceptorantibodyremovedbyimmunoadsorptioninpatientswithDCM,meanwhiletreatmentofheartfailureFollow-uponeyear,LVEFincreasing15%(22.3±3.3%to37.9±7.9%)
andLVEDddecreasing14.5%(74.5±7.1to63.7±6.0mm)inDCMgroup;LVEF(23.8±3.0to25.2±5.9%)noimprovement
andLVEDddecreased3.8%incontrolgroupTheclinicaltrialconfirmedthatremovingtheautoantibodiesmightimproveheartfunctioninDCMMüllerJ,etal.Circulation,2000,101:385-39SchimkeI,etal.JClinApher,2005,20:137-42精選課件ImmunomodulatingtherapyImmunomodulatingtherapywithintravenousimmunoglobulin2g/kginpatientswithchronicheartfailurewithin6monthsrecentlydiagnosedDCMAftertreated6monthsand12months,LVEFincreasing(0.25±0.08to0.41±0.17/6monthand0.42±0.14/12month)inpatientswithDCMThefindingsuggestsimmunoglobulinmight
regulatethebalanceofinflammatoryfactorand
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
- 4. 未經(jīng)權益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負責。
- 6. 下載文件中如有侵權或不適當內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 公司文件保密協(xié)議范本2024年
- 簽約注意事項2024年
- 冬季軍訓心得體會老師5篇
- 場與客戶雙重認可2024年
- 土建居間合同2024年
- 石灰采購合同2024年
- 工程項目招投標和合同管理緒論2024年
- 引進投資居間協(xié)議合同的模板2024年
- 2024-2025學年江蘇省連云港市九上數(shù)學開學綜合測試試題【含答案】
- 副食品供應合同協(xié)議書2024年
- 紙杯的設計方案
- 小組人員優(yōu)缺點分析報告
- 《彈簧測力計》說課稿、教案、教學設計與同步練習
- 國有企業(yè)員工法律知識講座
- 風濕免疫疾病的生活方式與自我管理方法
- 醫(yī)院臺風應急預案
- DB4201T622-2020燃氣管道設施安全保護規(guī)程
- 執(zhí)行力管理培訓課件
- 現(xiàn)場管理中的協(xié)作與溝通技巧
- 新興技術與知識產(chǎn)權保護的挑戰(zhàn)及解決方案
- 項目風險評估和緩解計劃
評論
0/150
提交評論